Myeloid Suppressors in Inflammation

University of South Florida

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Other

Identifiers

NCT01224223

MYELOID

Details and patient eligibility

About

Myeloid-derived suppressor cells (MDSC) have been studied for their ability to suppress T cell responses in vivo and in vitro. As a result, MDSC can regulate cellular responses to chronic inflammatory conditions such as cancer, leading to the induction of tolerance and, ultimately, tumor escape from immune surveillance.

Enrollment: 20 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion

1. Ages eligible for study: 18 to 60 years
2. Genders eligible for study: male and female
3. Signed and dated written informed consent is obtained prior to study blood draw.
4. Subjects being actively treated for chronic moderate to severe asthma based on National Heart Lung and Blood Institute guidelines (figure 1). Subjects must carry the diagnosis of asthma (made by a physician) for a minimum of six months.
5. Subjects within the first seven days of an acute asthma exacerbation, as determined by the referring physician.
6. Able to give informed consent.

Exclusion Criteria:

1. Use of systemic corticosteroids within the previous two weeks.
2. Pregnant and/or lactating females.
3. Current tobacco use.
4. Severe psychiatric illness.
5. Current illicit substance abuse or dependence and/or abuse of alcohol.
6. Current use of anti-microbial medications.
7. Primary or secondary immunodeficiency.
8. Any clinically significant uncontrolled medical condition that would put the patient's safety at risk.

Trial design

20 participants in 2 patient groups

acute asthma exaecerbtion patients

Description:

Patients experiencing acute exacerbation of their asthma

chronic asthma group

Description:

Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%